TherapeuticsMD, Inc. reported its financial results for the second quarter and first half of 2026, revealing a net income of $155,000 for the three months ending June 30, 2026, compared to $551,000 for the same period in 2025. For the first half of 2026, the company recorded a net income of $250,000, a significant improvement from a net loss of $102,000 in the first half of 2025. License revenue for the second quarter of 2026 was $869,000, down from $952,000 in the prior year, while total revenue for the first half increased to $1.593 million from $1.345 million, primarily driven by changes in sales of licensed products.
Operating expenses for the second quarter of 2026 rose slightly to $1.685 million from $1.647 million in the same quarter of 2025, attributed mainly to increased rent and press release costs. The company reported a loss from operations of $816,000 for the second quarter, compared to a loss of $695,000 in the previous year. However, total other income decreased to $980,000 from $1.240 million, reflecting lower income from Mayne Pharma's royalty sales and a one-time settlement received in 2025.
In terms of strategic developments, TherapeuticsMD transitioned to a pharmaceutical royalty company in December 2022, following a significant licensing agreement with Mayne Pharma. This agreement allows Mayne Pharma to commercialize several products, including IMVEXXY and BIJUVA, in exchange for royalties and milestone payments. As of June 30, 2026, the company had a royalty receivable of $3.394 million in the short term and $12.626 million in the long term, reflecting the minimum annual royalties owed by Mayne Pharma.
Operationally, the company has streamlined its workforce significantly, employing only one full-time employee as of June 30, 2026, following the termination of its executive management team in late 2022. The company has engaged external consultants to assist with ongoing operations and the wind-down of its previous commercial activities. Despite the challenges, including ongoing litigation with Mayne Pharma regarding contract disputes, TherapeuticsMD is exploring various strategic alternatives to enhance its financial position.
Looking ahead, the company expressed concerns about its liquidity and ability to continue as a going concern, emphasizing the need for additional capital to fund operations. TherapeuticsMD may pursue equity and debt financing options to address these needs, although market conditions could impact its ability to raise funds. The company remains focused on its royalty revenue model and the performance of its licensed products as it navigates these challenges.
About TherapeuticsMD, Inc.
TherapeuticsMD is a pharmaceutical royalty company specializing in women’s health products. It owns or licenses rights to products like IMVEXXY, BIJUVA, and ANNOVERA, generating revenue through royalties from licensed pharmaceutical products sold worldwide. The company focuses on licensing, patent protection, and strategic partnerships, relying on third-party manufacturers and licensees to commercialize its portfolio in various global markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov